175 related articles for article (PubMed ID: 21806967)
21. Characterization of a novel WHSC1-associated SET domain protein with H3K4 and H3K27 methyltransferase activity.
Kim SM; Kee HJ; Eom GH; Choe NW; Kim JY; Kim YS; Kim SK; Kook H; Kook H; Seo SB
Biochem Biophys Res Commun; 2006 Jun; 345(1):318-23. PubMed ID: 16682010
[TBL] [Abstract][Full Text] [Related]
22. NSD family proteins: Rising stars as therapeutic targets.
He L; Cao Y; Sun L
Cell Insight; 2024 Apr; 3(2):100151. PubMed ID: 38371593
[TBL] [Abstract][Full Text] [Related]
23. Substrate specificity analysis and novel substrates of the protein lysine methyltransferase NSD1.
Kudithipudi S; Lungu C; Rathert P; Happel N; Jeltsch A
Chem Biol; 2014 Feb; 21(2):226-37. PubMed ID: 24412544
[TBL] [Abstract][Full Text] [Related]
24. Nizp1 is a specific NUP98-NSD1 functional interactor that regulates NUP98-NSD1-dependent oncogenic programs.
Berardi A; Botrugno OA; Quilici G; Manteiga JMG; Bachi A; Tonon G; Musco G
FEBS J; 2023 Apr; 290(7):1782-1797. PubMed ID: 36271682
[TBL] [Abstract][Full Text] [Related]
25. Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity.
Kim JY; Kee HJ; Choe NW; Kim SM; Eom GH; Baek HJ; Kook H; Kook H; Seo SB
Mol Cell Biol; 2008 Mar; 28(6):2023-34. PubMed ID: 18172012
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of NSD2 and NSD3 in overgrowth syndromes.
Douglas J; Coleman K; Tatton-Brown K; Hughes HE; Temple IK; Cole TR; Rahman N;
Eur J Hum Genet; 2005 Feb; 13(2):150-3. PubMed ID: 15483650
[TBL] [Abstract][Full Text] [Related]
27. NSD1 is essential for early post-implantation development and has a catalytically active SET domain.
Rayasam GV; Wendling O; Angrand PO; Mark M; Niederreither K; Song L; Lerouge T; Hager GL; Chambon P; Losson R
EMBO J; 2003 Jun; 22(12):3153-63. PubMed ID: 12805229
[TBL] [Abstract][Full Text] [Related]
28. Structures of SET domain proteins: protein lysine methyltransferases make their mark.
Yeates TO
Cell; 2002 Oct; 111(1):5-7. PubMed ID: 12372294
[TBL] [Abstract][Full Text] [Related]
29. NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines.
Angrand PO; Apiou F; Stewart AF; Dutrillaux B; Losson R; Chambon P
Genomics; 2001 May; 74(1):79-88. PubMed ID: 11374904
[TBL] [Abstract][Full Text] [Related]
30. Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase.
Sun XJ; Wei J; Wu XY; Hu M; Wang L; Wang HH; Zhang QH; Chen SJ; Huang QH; Chen Z
J Biol Chem; 2005 Oct; 280(42):35261-71. PubMed ID: 16118227
[TBL] [Abstract][Full Text] [Related]
31. Low expression of NSD1, NSD2, and NSD3 define a subset of human papillomavirus-positive oral squamous carcinomas with unfavorable prognosis.
Gameiro SF; Ghasemi F; Zeng PYF; Mundi N; Howlett CJ; Plantinga P; Barrett JW; Nichols AC; Mymryk JS
Infect Agent Cancer; 2021 Feb; 16(1):13. PubMed ID: 33588906
[TBL] [Abstract][Full Text] [Related]
32. NSD1 PHD domains bind methylated H3K4 and H3K9 using interactions disrupted by point mutations in human sotos syndrome.
Pasillas MP; Shah M; Kamps MP
Hum Mutat; 2011 Mar; 32(3):292-8. PubMed ID: 21972110
[TBL] [Abstract][Full Text] [Related]
33. Structure, Activity and Function of the NSD3 Protein Lysine Methyltransferase.
Rathert P
Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440470
[TBL] [Abstract][Full Text] [Related]
34. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex.
Brown MA; Sims RJ; Gottlieb PD; Tucker PW
Mol Cancer; 2006 Jun; 5():26. PubMed ID: 16805913
[TBL] [Abstract][Full Text] [Related]
35. Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs.
Piao L; Gao Y; Xu X; Su Y; Wang YD; Zhou J; Gao Y; Fang J; Li Q; Chang S; Kong R
Eur J Med Chem; 2024 Mar; 268():116264. PubMed ID: 38412693
[TBL] [Abstract][Full Text] [Related]
36. The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate.
Li Y; Trojer P; Xu CF; Cheung P; Kuo A; Drury WJ; Qiao Q; Neubert TA; Xu RM; Gozani O; Reinberg D
J Biol Chem; 2009 Dec; 284(49):34283-95. PubMed ID: 19808676
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of Nuclear Receptor Binding SET Domain 2/Multiple Myeloma SET Domain by LEM-06 Implication for Epigenetic Cancer Therapies.
di Luccio E
J Cancer Prev; 2015 Jun; 20(2):113-20. PubMed ID: 26151044
[TBL] [Abstract][Full Text] [Related]
38. Structure of the Neurospora SET domain protein DIM-5, a histone H3 lysine methyltransferase.
Zhang X; Tamaru H; Khan SI; Horton JR; Keefe LJ; Selker EU; Cheng X
Cell; 2002 Oct; 111(1):117-27. PubMed ID: 12372305
[TBL] [Abstract][Full Text] [Related]
39. NSD2 as a Promising Target in Hematological Disorders.
Azagra A; Cobaleda C
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232375
[TBL] [Abstract][Full Text] [Related]
40. Targeting the Nuclear Receptor-Binding SET Domain Family of Histone Lysine Methyltransferases for Cancer Therapy: Recent Progress and Perspectives.
Shrestha A; Kim N; Lee SJ; Jeon YH; Song JJ; An H; Cho SJ; Kadayat TM; Chin J
J Med Chem; 2021 Oct; 64(20):14913-14929. PubMed ID: 34488340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
